Xolair® (omalizumab) – New indication
December 1, 2020 - Genentech announced the FDA approval of Xolair (omalizumab), for add-on maintenance treatment of nasal polyps in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
Download PDF
